Investigational New Drug, Eque-cel, Receives FDA Approval for Lupus Nephritis and Non-Renal Systemic Lupus Erythematosus Treatment
The new drug application for the investigational therapy, Equecabtagene Autoleucel or Eque-cel, for treatment of lupus nephritis (LN) and non-renalsystemic lupus erythematosus (SLE) was approved by the U.S. Food and Drug Administration.
Eque-cell is a fully human B-cell maturation antigen (anti-BCMA) CAR T cell therapy injection designed to help reset the immune system. The therapy targets and destroys BCMA-expressing cells, eliminates activated B-cells and plasma cells in people with SLE, calms autoimmune inflammation and eases disease symptoms.
The therapy has been proven to be safe and effective for treatment of relapsed/refractoryautoantibody-mediated neurological diseases. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.